FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.
Stephanie Pilat, PharmD
Advertisement
Articles by Stephanie Pilat, PharmD
This study highlights one benefit of the integrated health system specialty pharmacy model for patients who are prescribed acalabrutinib.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First OTC Acetaminophen-Naproxen Combination for 12-Hour Pain Relief
2
Vaccine Guidance Is Rapidly Changing—Here's What You Need to Know
3
Online GLP-1 Sellers Often Skip Clinician Oversight, Secret Shopper Study Finds
4
What Real-World Data Show About Moving Patients From Humira to Biosimilars
5